Sandi See Tai, MD, is the Chief Development Officer at Lexeo Therapeutics, a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease. In her role, she is responsible for driving portfolio clinical development strategy and program execution.

Prior to Lexeo, Dr. See Tai was Vice President, Development Head for Rare Disease at Pfizer, responsible for setting the Rare Disease internal portfolio and business development strategy, and delivering its clinical development portfolio of investigational products and in-line assets. She served as the Medicine Team Lead for programs across multiple therapeutic areas including Rare Cardiac, Neuro, Renal and Pulmonary, and achieved global regulatory approvals of novel treatments for rare diseases.

With 20 years of experience in the pharmaceutical industry, Dr. See Tai has held multiple roles of increased scope and responsibilities across Clinical Development and Global Medical Affairs at Wyeth Pharmaceuticals and Pfizer.

Prior to joining the pharmaceutical industry, Dr. See Tai was Assistant Professor of Pediatrics at Drexel University College of Medicine and Attending Physician in Pediatric Nephrology at St. Christopher’s Hospital for Children, Philadelphia, where she had also completed her General Pediatrics residency and Pediatric Nephrology fellowship. She received her MD from Tufts University School of Medicine, Boston.